To the Moon? What is going on with APLS?

This afternoon we watched Apellis Pharmaceuticals rise 14.3% to a price of $61.58 per share. The mid-cap None company is now trading -13.5% below its average target price of $71.19. Analysts have set target prices ranging from $44.0 to $95.0 per share for Apellis Pharmaceuticals, and have given the stock an average rating of buy.

Apellis Pharmaceuticals has an elevated short interest of 15.8%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 8.36. Since 13.63% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. 96.8% of Apellis Pharmaceuticals shares are held by institutional investors, which indicates a high level of confidence in the stock.

Institutions Invested in Apellis Pharmaceuticals

Date Reported Holder Percentage Shares Value
2023-09-30 Wellington Management Group, LLP 13% 15,167,044 $933,986,597
2023-09-30 Avoro Capital Advisors LLC 9% 11,111,111 $684,222,235
2023-09-30 EcoR1 Capital, LLC 9% 10,899,859 $671,213,337
2023-09-30 Vanguard Group Inc 8% 9,469,977 $583,161,201
2023-09-30 T. Rowe Price Investment Management, Inc. 6% 6,519,471 $401,469,036
2023-09-30 Blackrock Inc. 4% 5,272,746 $324,695,708
2023-09-30 Jennison Associates LLC 3% 3,542,209 $218,129,236
2023-09-30 State Street Corporation 3% 3,238,114 $199,403,066
2023-09-30 Octagon Capital Advisors LP 3% 3,130,000 $192,745,405
2023-09-30 FMR, LLC 2% 2,259,766 $139,156,394

For these reasons, we consider that the Apellis Pharmaceuticals is the subject of None.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS